Let The Games Begin: Celltrion Sets Sights On Global Markets After Approval Of Remicade Biosimilar In Korea
This article was originally published in PharmAsia News
Executive Summary
In addition to Remicade, Celltrion has seven other biosimilars in development, including versions of Roche’s MabThera and Herceptin.